Cancer Vaccines with Potential | GenomeWeb

Cancer Vaccines with Potential


When Dendreon came out with its prostate cancer vaccine Provenge, researchers jumped on the vaccine bandwagon and Wall Street salivated at the thought of the billions of dollars it was going to make, says Robert Langreth at the Forbes Treatments blog. But the complicated preparation for the treatment and the $93,000 price tag — not to mention confusion over how it works since it extends life without slowing tumor growth — have caused big pharmaceutical companies to shy away from trying to develop a vaccine of their own, Langreth adds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.